Friday 6 November 2026
Export ALGN’s income statement to Excel — free account
Align Technology, Inc.
ALGN Healthcare Medical Instruments & Supplies
Align Technology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, up 0.90% from fiscal 2024.
- Revenue
- +1.92%
- EPS
- +143.9%
- Free cash flow
- +8.26%
Quarter to September 2026, against a year earlier
158.87
6.03
−3.66%
Follow ALGN
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
21.12 | 29.28 | 28.72 | 27.59 |
+8 more quarters Free account |
P/S ratio |
2.48 | 2.91 | 2.99 | 2.81 | |
P/FCF ratio |
15.41 | 17.85 | 20.98 | 23.08 | |
P/Operating CF |
56.41 | 62.56 | 81.07 | 50.76 | |
P/B ratio |
2.44 | 2.85 | 2.95 | 2.80 | |
Price to Tangible BV |
2.83 | 3.31 | 3.45 | 3.27 | |
EV/Sales |
2.21 | 2.65 | 2.73 | 2.54 | |
EV/EBITDA |
11.44 | 13.66 | 13.78 | 13.07 | |
EV/Operating CF |
12.23 | 14.50 | 16.17 | 17.25 | |
EV/FCF |
13.70 | 16.22 | 19.16 | 20.85 | |
Quick Ratio |
1.21 | 1.18 | 1.15 | 1.14 | |
Current Ratio |
1.42 | 1.40 | 1.39 | 1.36 | |
Net Debt/EBITDA |
0.00 | (5.68) | (5.34) | (4.26) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.65 | 0.66 | 0.66 | 0.65 | |
Operating CF/Net income |
1.35 | 1.78 | 1.34 | 1.64 | |
Capex/Depreciation |
— | 0.16 | (0.54) | (0.35) | |
Research and Development Expense of Revenue |
9.25% | 9.66% | 9.49% | 7.93% | |
Selling, General and Administrative Expense of Revenue |
40.46% | 43.81% | 44.74% | 42.16% | |
Intangible Assets out of Total Assets |
0.09 | 0.09 | 0.10 | 0.09 | |
Share Based Compensation of Revenue |
0.00% | 4.31% | 3.93% | 4.23% | |
Graham Net Nets |
0.05 | 0.04 | 0.04 | 0.04 | |
Graham Number |
0.00 | 87.59 | 88.34 | 84.31 | |
Earnings Yield |
4.73% | 3.42% | 3.48% | 3.62% | |
Free Cash Flow Yield |
6.49% | 5.60% | 4.77% | 4.33% | |
Revenue per Share |
14.29 | 14.77 | 14.56 | 14.44 | |
Operating CF per Share |
2.58 | 2.70 | 2.11 | 3.08 | |
Capex per Share |
0.00 | 0.09 | (0.43) | (0.50) | |
Free Cash Flow per Share |
2.58 | 2.78 | 1.68 | 2.58 | |
Cash per Share |
16.13 | 15.42 | 14.84 | 15.09 | |
Shareholders Equity per Share |
60.65 | 59.20 | 58.09 | 55.82 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
60.65 | 59.20 | 58.09 | 55.82 | |
Free Cash Flow |
182.92 | 199.09 | 120.26 | 187.26 | |
Working Capital |
812.58 | 754.45 | 749.58 | 696.55 | |
Capital Expenditures |
— | 6.34 | (30.78) | (35.92) | |
Net Current Asset Value |
511.04 | 477.92 | 490.68 | 432.02 | |
EV/EBIT |
14.79 | 20.01 | 20.09 | 18.75 | |
Capex to Sales |
0.00 | (0.01) | 0.03 | 0.03 | |
Price to Operating Income |
16.63 | 22.02 | 22.00 | 20.76 | |
| Other line items | |||||
Average Receivables |
1,131.61 | 1,132.30 | 1,093.55 | 1,048.72 | |
Average Payables |
121.71 | 112.14 | 124.55 | 115.07 | |
Average Inventory |
226.41 | 228.00 | 230.76 | 240.32 | |
Average Assets |
6,377.08 | 6,318.34 | 6,208.50 | 6,224.15 | |
Average Common Equity |
— | 4,072.62 | 3,971.83 | 3,950.57 |
Columns are period end dates · fundamentals updated 2 Nov 2026